Close Menu

People in the News

Apr 05, 2019

Karen Koski

Karen Koski has been appointed the chief business officer for Specific Diagnostics, effective April 8. She was previously with Oxford Immunotec as vice president of strategy and investor relations. Prior to that, she was a director and senior equity analyst at BTIG. 

Apr 03, 2019

Ilan Daskal

Bio-Rad Laboratories has appointed Ilan Daskal as executive vice president and CFO. Daskal previously served as CFO of Lumileds, a lighting manufacturer formed in 1999 as a joint venture between Philips Lighting and Agilent Technologies. He will replace Christine Tsingos, who is retiring.

Apr 03, 2019

Parag Mallick

Parag Mallick has been appointed to the scientific board of Oncimmune Holdings. He is an associaate professor of radiology at Stanford University and a member of the Canary Center for Cancer Early Detection. His research focuses on approaches using big data, mathematical modeling, and machine learning to discover cancer biomarkers for personalized and predictive medicine. 

Apr 02, 2019

Michael Deppe

Quest Diagnostics said in a document filed with the US Securities and Exchange Commission that Michael Deppe was elected vice president, corporate controller and chief accounting officer and the company's principal accounting officer. Deppe joined Quest in 1998 and has served in various account and finance leadership positions, including president of finance-enterprise operation and IT from August 2015 to March 2019. Before joining the company, he started his career at PricewaterhouseCoopers. 

Apr 02, 2019

Flemming Ornskov

Flemming Ornskov was appointed to Centogene's supervisory board and elected its non-executive chairman, effective April 1. He most recently was CEO of Shire. Prior to that, he held senior positions at several pharmaceutical firms, such as Bayer, Novartis, and Merck & Co. As a non-executive chairman, Ornskov will oversee Centogene's strategy development, US expansion, and strategic M&A. 

Apr 02, 2019

Steve Fletcher, Tim Dwyer, Joseph Fitchett, Stephen Crossland, Andrew Wheeler

Mologic has announced the opening of a US subsidiary and key appointments for its US and United Kingdom sites.

The firm announced Steve Fletcher as president and chief commercial officer of Mologic Inc. and head of the firm's US headquarters located just outside of Boston, Massachusetts.

Fletcher has more than 25 years of experience in leading marketing, product, and business operations for global healthcare companies, including 3M, Thermo Fisher Scientific, and GC America.

Mologic also appointed Tim Dwyer as its chief technology officer. Dwyer is a fellow of the Royal Society of Biology with more than 19 years of experience in the design and development of diagnostic devices on multiple immunoassay platform technologies.

The firm appointed Joseph Fitchett as its chief medical officer and head of global health to support the expansion of its UK facilities. In his previous role as a program officer at the Bill & Melinda Gates Foundation, Fitchett advanced the foundation’s bilateral partnerships with European Union donors, including advancing the manufacturing capacity of yellow fever vaccine and infectious disease surveillance and control, at the Institut Pasteur in Dakar.

In the US, Mologic also appointed Stephen Crossland as vice president of sales and business development and Andrew Wheeler as R&D manager.

Apr 01, 2019

Marc Williams, Karen Gripp, Dietrich Matern, Michael Murray, Cynthia Powell, Heidi Rehm

Marc Williams has been announced as president-elect of the American College of Medical Genetics and Genomics. He is the director of the Geisinger Genomic Medicine Institute. Prior to joining Geisinger in 2012, he was the director of Intermountain Healthcare's Clinical Genetics Institute. Williams is a board-certified pediatrician and holds an MD as well as an undergraduate degree in chemistry from the University of Wisconsin-Madison.

Williams and five others have also been elected to the ACMG's board of directors for a six-year term that starts this month. The other new directors are Karen Gripp, chief of the Division of Medical Genetics at the Nemours/Alfred I. duPont Hospital for Children and medical director of its molecular diagnostics laboratory; Dietrich Matern, chair of the Division of Laboratory Genetics and Genomics in the Department of Laboratory Medicine and Pathology at the Mayo Clinic; Michael Murray, director of clinical operations in the Center for Genomic Health at Yale University School of Medicine; Cynthia Powell, director of the medical residency program and medical director of the UNC Hospitals Cytogenetics Laboratory; and Heidi Rehm, chief genomics officer at Massachusetts General Hospital and medical director of the Broad Institute's clinical laboratory.

Mar 29, 2019

Amol Chaubal

Quanterix said this week that it has appointed Amol Chaubal as CFO, effective April 12, 2019. He replaces Joseph Driscoll, who is stepping down as CFO. Chaubal joins Quanterix from medical device firm Smith & Nephew, where he currently serves as CFO of global operations. Prior to Smith & Nephew, he served as corporate VP and head of finance for Parexel's CRS business, and has also held various roles at Novartis, including CFO North America – Vaccines & Diagnostics.

Mar 28, 2019

Bob Petrou

NantHealth has removed the "interim" tag from CFO Bob Petrou, company CEO Patrick Soon-Shiong disclosed today in a conference call with reporters and financial analysts. Petrou joined NantHealth in September following the resignation of former CFO Paul Holt.

Mar 27, 2019

Lloyd Sanders

Epic Sciences has appointed Lloyd Sanders as president and CEO. He will be replacing Murali Prahalad, who is stepping down and has been appointed to the board of directors. Sanders joins the firm with 20 years of diagnostic and pharmaceutical industry experience. He previously served as president of Myriad Genetics' oncology segment. Prior to Myriad, Sanders served as chief operating officer at Dey Pharma. Before Dey Pharma, Sanders worked at Genta, where he acted as VP of marketing and later COO.

Mar 27, 2019

Colin Bier

Todos Medical appointed Colin Bier to its board of directors. Bier has more than 35 years of clinical expertise, has experience in commercializing diagnostic tests, and has participated in clinical trials, including for Alzheimer's disease.

He previously served as a scientific advisor to and chief development officer of Amarantus Diagnostics.

Todos Medical said that Bier has familiarity with its recent joint venture and the science of LymPro, a diagnostic test for Alzheimer's Disease.

Mar 21, 2019

Richard Altieri, Matthew McLaughlin, Elizabeth Keiley

Richard Altieri, chief financial officer for Oxford Immunotec, will retire on April 30, 2019. The company has appointed as his successor Matthew McLaughlin, currently CFO for GE Healthcare, US and Canada, a position he has held since December 2016. Prior to that he worked at GW Aviation, serving as CFO of Global Supply Chain from May 2014 to December 2016, CFO of GE Avionics from March 2012 to April 2014, and executive in financial planning and analysis from 2009 to February 2012.

Oxford Immunotec also disclosed in a filing with the US Securities and Exchange Commission that Elizabeth Keiley, senior vice president, general counsel, has resigned.

Mar 14, 2019

Michael Ball

Contextual Genomics has appointed Michael Ball as the firm's CEO. He previously served as global VP of commercial, informatics, at Illumina. Prior to Illumina, Ball acted as CEO of GenoLogics Life Sciences Software. He is currently a director of the Canary Foundation, a non-profit focused on early cancer detection.

Mar 13, 2019

Stephen Brecher

First Light Diagnostics has added Stephen Brecher to its clinical advisory board. He has been a practicing clinical microbiologist for 50 years and is the director of microbiology at the VA Boston HealthCare System, as well as an associate professor of pathology and laboratory medicine at the Boston University School of Medicine. He also is on the editorial board of the Journal of Clinical Microbiology.

Mar 12, 2019

Phi Vu

Phi Vu has joined AdvaMedDx as its vice president. Vu was the director for health policy at the Biotechnology Innovation Organization. Previous to that he was in the US Department of Defense's Chemical and Biological Defense Program. AdvaMedDx is a division of the Advanced Medical Technology Association focusing on the value that diagnostics to healthcare.

Mar 12, 2019

Norman Sharpless

The US Health and Human Services Secretary Alex Azar has appointed Norman Sharpless as acting commissioner of the US Food and Drug Administration. Sharpless, currently the director of the National Cancer Institute, will take over for current FDA Commissioner Scott Gottlieb who announced on March 5 that he will resign from the post in one month. Before his position at the NCI, Sharpless directed the University of North Carolina's Lineberger Comprehensive Cancer Center, authored more than 100 research papers, and treated leukemia patients.

Mar 12, 2019

Patricia Rivera

Bioaffinity Technologies has formed a scientific and medical advisory board and named Patricia Rivera as the chairperson. Rivera is a professor of pulmonary diseases and critical care medicine at the University of North Carolina School of Medicine. She is also director of the UNC Lung Cancer Screening Clinic.

Mar 12, 2019

David Hoak, Bruce Beckwith, Eric Glassy, John Spinosa

Gestalt Diagnostics has created an advisory board, which is being led by the company's medical director David Hoak. Other members include Bruce Beckwith, chairman of pathology of North Shore Medical Center in Salem, Massachusetts; Eric Glassy, director of pathology at Providence Little Company of Mary Medical Center in San Pedro, California; and John Spinosa, chief medical officer at the San Diego Blood Bank. 

 

Mar 12, 2019

Rick Wenstrup

Rick Wenstrup has stepped down as chief medical officer at Oxford Immunotec, the company disclosed during an earnings call this week. Prior to joining Oxford Immunotec, Wenstrup was executive vice president and CMO for Myriad Genetics. He also previously served as CMO for Myriad Genetic Laboratories.

Mar 04, 2019

Robert Klug

Quest Diagnostics reported this week that Robert Klug, the company's vice president, controller, and chief accounting officer, will be leaving Quest on May 1. He will remain at his current position until then or until a successor is named, whichever occurs first, Quest said in a document filed with the US Securities and Exchange Commission. It did not give a reason for his departure. 

Mar 04, 2019

Kathleen Sebelius

Exact Sciences has appointed Kathleen Sebelius to serve as a director on its board. She will sit on the firm's corporate governance and nominating committee and on its innovation, technology and pipeline committee. Sebelius currently serves as CEO of Sebelius Resources, a strategic consulting firm that advises private companies, non-profit organizations, and financial investors. From April 2009 through June 2014, she served as the Health and Human Services Secretary for President Barack Obama. She also served as Governor of Kansas from 2003 to 2009, and her previous elected offices include two terms as the Kansas insurance commissioner and four terms in the Kansas legislature.

Sebelius currently sits on the boards of biopharmaceutical companies Dermira and Myovant Sciences, as well as the Kaiser Family Foundation. She also co-chairs the Aspen Institute Health Strategy Group and serves on advisory boards for the Dole Institute of Politics, Solera Health, Out Leadership, the Estée Lauder Foundation, and the University of Kansas College of Liberal Arts and Sciences.

Feb 27, 2019

Todd Wood

DermTech has appointed Todd Wood as the firm's chief commercial officer. Wood brings 25 years of pharmaceutical and medical device commercialization experience to the firm. He has previously launch multiple market products, including Juvéderm, Limigan, and Rhofade.

Feb 27, 2019

Jan Lundberg

Jan Lundberg has joined Metabolon's board of directors. He was most recently the president of Lilly Research Labs and head of R&D at Eli Lilly, and has held management positions at AstraZeneca and the Karolinska Institute. Lundberg is also the cofounder of Aerocrine and currently serves on the boards of Ardelyx, Betagenon Image Analysis Group, and TB Alliance. He will be an independent director at Metabolon. 

Feb 26, 2019

Jack Crowley, Kavita Patel, Garry Nicholson

Personal Genome Diagnostics has appointed Jack Crowley as its chief financial officer. Crowley most recently served as CFO at Lantheus Medical Imaging, where he led a transition from a private equity-backed to a publicly-traded global life sciences company. Prior to serving as CFO, Crowley also served as Lantheus' chief accounting officer, VP of finance, and global corporate controller. He also served as director of finance and assistant corporate controller at Biogen and director of accounting at Thermo Fischer Scientific. A Certified Public Accountant, he holds an MBA from the University of Massachusetts and a BS in Business Administration from Westfield State University.

PGDx has also appointed Kavita Patel and Garry Nicholson to its board of directors. Patel has served in the Obama Administration as director of policy for the Office of Intergovernmental Affairs and Public Engagement in the White House. Prior to the White House, she served as deputy staff director on health on the late Senator Edward Kennedy's staff. She also serves on the board of directors at Dignity Health and SSM Health Care. 

Nicholson currently serves as director at Five Prime Therapeutics, G1 Therapeutics, Tmunity Therapetics Inc, and SQZ Biotechnology. He previously served as President and CEO of XTuit Pharmaceuticals, as well as a member of the firm's board of directors. Prior to that, he served as president of Pfizer Oncology. He has also served on the Pfizer Foundation's board of directors and was a member of the firm's Portfolio, Strategy, and Investment Committee. In addition, Nicholson previously held leadership positions in the oncology division of Eli Lily. 

Feb 25, 2019

Don Elsey

OpGen has appointed Don Elsey to its board of directors and as the chairman of its audit committee. Elsey previously served as chief financial officer of Senseonics from 2015 to 2019. Prior to Senseonics, Elsey served as CFO of Regado Biosciences. He as also served as CFO of LifeCell and Emergent Biosolutions. In addition, Elsey has held senior financial positions at BioVeris, Igen, and PE (Applera). 

Pages